Table 1 Baseline patient characteristics (N = 2198)
From: Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology
Characteristic | Serum 25(OH)D levels | p-value | |
|---|---|---|---|
| Â | < = 32 ng/ml (n = 1651) | > 32 ng/ml (n = 547) | Â |
Gender | Â | Â | Â |
   Males | 628 (77.1) | 186 (22.9) | Chi-square |
   Females | 1023 (73.9) | 361 (26.1) | 0.09 |
Age at Presentation | Â | Â | Â |
   Mean | 55.2 | 55.7 | 2 sample t-test |
   Median | 55.9 | 55.8 | 0.32 |
   Range | 18.6 - 92.1 | 21.1 - 89.6 |  |
Treatment history | Â | Â | Â |
   Newly Diagnosed | 769 (73.2) | 282 (26.8) | Chi-square |
   Previously Treated | 882 (76.9) | 265 (23.1) | 0.04 |
Cancer Site | Â | Â | Â |
   Breast | 347 (69.4) | 153 (30.6) |  |
   Lung | 268 (81.7) | 60 (18.3) |  |
   Pancreas | 157 (73.4) | 57 (26.6) | Chi-square |
   Colorectal | 174 (85.3) | 30 (14.7) | < 0.001 |
   Prostate | 132 (71.4) | 53 (28.6) |  |
   Others | 573 (74.7) | 194 (25.3) |  |
Stage at Diagnosis | Â | Â | Â |
   Stage 0 | 21 (75) | 7 (25) |  |
   Stage 1 | 194 (73.2) | 71 (26.8) |  |
   Stage 2 | 332 (73.8) | 118 (26.2) | Chi-square |
   Stage 3 | 394 (76.7) | 120 (23.3) | 0.76 |
   Stage 4 | 566 (74.8) | 191 (25.2) |  |
   Indeterminate | 144 (78.3) | 40 (21.7) |  |